Singlera Genomics Closes $150M Series B Financing Round
The company is developing a liquid biopsy technology that uses circulating tumor DNA methylation signatures for the early detection of cancer.
Data Supports Singlera's PanSeer Test as Company Narrows Focus to Colorectal Cancer Detection
The company recently had a second pre-submission with FDA and expects to begin a prospective trial of its test in the second half of this year.
Where'd the Money Go? For Investments in Diagnostics in 2018, Usually to Cancer Test Development
Excluding IPOs, the funding environment for private venture-backed financing Dx deals in the US and Europe was remarkably similar in 2018 to 2017, according to Silicon Valley Bank.
Singlera Genomics Presents Data on Cell-Free DNA Methylation Test for Early Cancer Detection
The firm plans to conduct a prospective trial of a pan cancer assay and aims to bring another assay focused on colorectal cancer through FDA clearance.
Singlera to Use $60M Funding to Support Launch of IVDs, Research Into Very Early Detection of Cancer
The firm also offers an NIPT, codeveloped with Yale, that its CEO said is differentiated by its rapid time-to-result.